Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025CellsOpen Access

CRISPR-Powered Liquid Biopsies in Cancer Diagnostics

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJoshua R. SlatteryYNYe NaungBKBernd H. Kalinna

Discussion

Loading...

Member takes

Overview

This review demonstrates the effectiveness of CRISPR diagnostics for cancer biomarkers, suggesting advancements for point-of-care testing.

Key Points

  • Using CRISPR diagnostics improves the detection of cancer biomarkers in liquid biopsies, enabling earlier diagnosis.
  • Markers in peripheral blood samples include circulating tumour nucleic acids, which are critical for cancer diagnostics.
  • The integration of nucleic acid amplification with CRISPR enhances sensitivity and specificity comparable to established laboratory techniques.
  • CRISPR assays present unique advantages for point-of-care applications, facilitating faster and easier development than traditional assays.

Cite This Study

Slattery et al. (2025) studied this question.

synapsesocial.com/papers/68de5da783cbc991d0a20e8ahttps://doi.org/10.3390/cells14191539
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories2025
  2. 2Liquid Biopsy in Oncology: Revolutionizing Early Detection and Monitoring2025
  3. 3Liquid biopsy: current technology and clinical applications2022 · 932 citations
  4. 4The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer2025
  5. 5CRISPR-Based Diagnostics for Circulating Cell-Free DNA: A Paradigm Shift in Precision Oncology2025